Moleculin Biotech (MBRX) Competitors $0.67 +0.04 (+5.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.66 0.00 (-0.62%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ANRO, EPIX, EXOZ, CABA, BYSI, ELUT, MIST, CELU, IPA, and SRZNShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Alto Neuroscience (ANRO), ESSA Pharma (EPIX), eXoZymes (EXOZ), Cabaletta Bio (CABA), BeyondSpring (BYSI), Elutia (ELUT), Milestone Pharmaceuticals (MIST), Celularity (CELU), ImmunoPrecise Antibodies (IPA), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Alto Neuroscience ESSA Pharma eXoZymes Cabaletta Bio BeyondSpring Elutia Milestone Pharmaceuticals Celularity ImmunoPrecise Antibodies Surrozen Alto Neuroscience (NYSE:ANRO) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the media prefer ANRO or MBRX? In the previous week, Alto Neuroscience had 20 more articles in the media than Moleculin Biotech. MarketBeat recorded 24 mentions for Alto Neuroscience and 4 mentions for Moleculin Biotech. Alto Neuroscience's average media sentiment score of -0.02 beat Moleculin Biotech's score of -0.07 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ANRO or MBRX? Alto Neuroscience presently has a consensus target price of $8.50, indicating a potential upside of 177.78%. Moleculin Biotech has a consensus target price of $4.00, indicating a potential upside of 501.41%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ANRO or MBRX? Alto Neuroscience has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Which has preferable valuation and earnings, ANRO or MBRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.34-1.31Moleculin BiotechN/AN/A-$21.76MN/AN/A Do insiders & institutionals believe in ANRO or MBRX? 15.5% of Moleculin Biotech shares are held by institutional investors. 11.1% of Alto Neuroscience shares are held by company insiders. Comparatively, 2.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ANRO or MBRX more profitable? Alto Neuroscience's return on equity of -39.35% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -39.35% -33.86% Moleculin Biotech N/A -278.80%-100.11% SummaryAlto Neuroscience beats Moleculin Biotech on 7 of the 11 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.97M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.388.508.275.54Net Income-$21.76M-$55.06M$3.25B$259.28M7 Day Performance17.30%-3.99%-3.70%-4.64%1 Month Performance91.40%9.58%4.34%4.41%1 Year Performance-74.32%6.70%25.90%17.95% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.6933 of 5 stars$0.67+5.9%$4.00+501.4%-70.7%$18.97MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap DownANROAlto Neuroscience1.8576 of 5 stars$3.10+1.5%$8.50+174.6%-68.6%$83.78MN/A-1.32N/ANews CoverageEPIXESSA Pharma1.1884 of 5 stars$1.88+0.3%$2.00+6.7%-63.4%$83.23MN/A-2.9850News CoverageUpcoming EarningsEXOZeXoZymesN/A$9.93-1.9%N/AN/A$83.11M$70K0.0029CABACabaletta Bio1.8014 of 5 stars$1.64+4.1%$14.43+782.5%-79.1%$82.96MN/A-0.6450Positive NewsUpcoming EarningsGap UpBYSIBeyondSpringN/A$2.03+1.0%N/A+6.7%$81.85M$1.75M0.0080Positive NewsELUTElutia3.4514 of 5 stars$1.95+6.0%$8.00+310.3%-40.4%$80.18M$24.38M-1.01180News CoverageUpcoming EarningsGap DownMISTMilestone Pharmaceuticals1.8184 of 5 stars$1.49+1.7%$7.00+371.4%+2.9%$79.39M$1M-1.9030Positive NewsUpcoming EarningsShort Interest ↑CELUCelularity0.2161 of 5 stars$3.30+3.4%N/A-1.0%$79.04M$54.22M-1.25220News CoverageUpcoming EarningsAnalyst UpgradeIPAImmunoPrecise Antibodies2.0421 of 5 stars$1.73-0.3%$4.00+131.9%+90.0%$78.94M$18.16M-1.4980News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionSRZNSurrozen1.8428 of 5 stars$9.05-2.2%$38.50+325.6%+36.1%$77.43M$10.65M-0.3680Gap Down Related Companies and Tools Related Companies ANRO Competitors EPIX Competitors EXOZ Competitors CABA Competitors BYSI Competitors ELUT Competitors MIST Competitors CELU Competitors IPA Competitors SRZN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts